GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 766.85
3 061.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Cash from Financing Activities
GlaxoSmithKline Pharmaceuticals Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
Cash from Financing Activities
-₹5.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Financing Activities
₹30.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Financing Activities
-₹16.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Financing Activities
-₹58.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Financing Activities
-₹26.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash from Financing Activities
₹52.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.
See Also
What is GlaxoSmithKline Pharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
-5.7B
INR
Based on the financial report for Sep 30, 2024, GlaxoSmithKline Pharmaceuticals Ltd's Cash from Financing Activities amounts to -5.7B INR.
What is GlaxoSmithKline Pharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-2%
Over the last year, the Cash from Financing Activities growth was -1%. The average annual Cash from Financing Activities growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been -2% over the past three years .
You don't have any saved screeners yet
